Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1997 Apr;71(4):3031–3038. doi: 10.1128/jvi.71.4.3031-3038.1997

Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector.

I J Caley 1, M R Betts 1, D M Irlbeck 1, N L Davis 1, R Swanstrom 1, J A Frelinger 1, R E Johnston 1
PMCID: PMC191432  PMID: 9060663

Abstract

A molecularly cloned attenuated strain of Venezuelan equine encephalitis virus (VEE) has been genetically configured as a replication-competent vaccine vector for the expression of heterologous viral proteins (N. L. Davis, K. W. Brown, and R. E. Johnston, J. Virol. 70:3781-3787, 1996). The matrix/capsid (MA/CA) coding domain of human immunodeficiency virus type 1 (HIV-1) was cloned into the VEE vector to determine the ability of a VEE vector to stimulate an anti-HIV immune response in mice. The VEE-MA/CA vector replicated rapidly in the cytoplasm of baby hamster kidney (BHK) cells and expressed large quantities of antigenically identifiable MA/CA protein. When injected subcutaneously into BALB/c mice, the vector invaded and replicated in the draining lymphoid tissues, expressing HIV-1 MA/CA at a site of potent immune activity. Anti-MA/CA immunoglobulin G (IgG) and IgA antibodies were present in serum of all immunized mice, and titers increased after a second booster inoculation. IgA antibodies specific for MA/CA were detected in vaginal washes of mice that received two subcutaneous immunizations. Cytotoxic T-lymphocyte responses specific for MA/CA were detected following immunization with the MA/CA-expressing VEE vector. These findings demonstrate the ability of a VEE-based vaccine vector system to stimulate a comprehensive humoral and cellular immune response. The multifaceted nature of this response makes VEE an attractive vaccine for immunization against virus infections such as HIV-1, for which the correlates of protective immunity remain unclear, but may include multiple components of the immune system.

Full Text

The Full Text of this article is available as a PDF (646.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altmeyer R., Escriou N., Girard M., Palmenberg A., van der Werf S. Attenuated Mengo virus as a vector for immunogenic human immunodeficiency virus type 1 glycoprotein 120. Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9775–9779. doi: 10.1073/pnas.91.21.9775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Berglund P., Sjöberg M., Garoff H., Atkins G. J., Sheahan B. J., Liljeström P. Semliki Forest virus expression system: production of conditionally infectious recombinant particles. Biotechnology (N Y) 1993 Aug;11(8):916–920. doi: 10.1038/nbt0893-916. [DOI] [PubMed] [Google Scholar]
  3. Berman P. W., Gregory T. J., Riddle L., Nakamura G. R., Champe M. A., Porter J. P., Wurm F. M., Hershberg R. D., Cobb E. K., Eichberg J. W. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature. 1990 Jun 14;345(6276):622–625. doi: 10.1038/345622a0. [DOI] [PubMed] [Google Scholar]
  4. Burke D. S., Ramsburg H. H., Edelman R. Persistence in humans of antibody to subtypes of Venezuelan equine encephalomyelitis (VEE) virus after immunization with attenuated (TC-83) VEE virus vaccine. J Infect Dis. 1977 Sep;136(3):354–359. doi: 10.1093/infdis/136.3.354. [DOI] [PubMed] [Google Scholar]
  5. Davis N. L., Brown K. W., Greenwald G. F., Zajac A. J., Zacny V. L., Smith J. F., Johnston R. E. Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1. Virology. 1995 Sep 10;212(1):102–110. doi: 10.1006/viro.1995.1458. [DOI] [PubMed] [Google Scholar]
  6. Davis N. L., Brown K. W., Johnston R. E. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. J Virol. 1996 Jun;70(6):3781–3787. doi: 10.1128/jvi.70.6.3781-3787.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Davis N. L., Powell N., Greenwald G. F., Willis L. V., Johnson B. J., Smith J. F., Johnston R. E. Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus: construction of single and multiple mutants in a full-length cDNA clone. Virology. 1991 Jul;183(1):20–31. doi: 10.1016/0042-6822(91)90114-q. [DOI] [PubMed] [Google Scholar]
  8. Davis N. L., Willis L. V., Smith J. F., Johnston R. E. In vitro synthesis of infectious venezuelan equine encephalitis virus RNA from a cDNA clone: analysis of a viable deletion mutant. Virology. 1989 Jul;171(1):189–204. doi: 10.1016/0042-6822(89)90526-6. [DOI] [PubMed] [Google Scholar]
  9. Girard M., Kieny M. P., Pinter A., Barre-Sinoussi F., Nara P., Kolbe H., Kusumi K., Chaput A., Reinhart T., Muchmore E. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci U S A. 1991 Jan 15;88(2):542–546. doi: 10.1073/pnas.88.2.542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Girard M., Meignier B., Barré-Sinoussi F., Kieny M. P., Matthews T., Muchmore E., Nara P. L., Wei Q., Rimsky L., Weinhold K. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J Virol. 1995 Oct;69(10):6239–6248. doi: 10.1128/jvi.69.10.6239-6248.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Grieder F. B., Davis N. L., Aronson J. F., Charles P. C., Sellon D. C., Suzuki K., Johnston R. E. Specific restrictions in the progression of Venezuelan equine encephalitis virus-induced disease resulting from single amino acid changes in the glycoproteins. Virology. 1995 Feb 1;206(2):994–1006. doi: 10.1006/viro.1995.1022. [DOI] [PubMed] [Google Scholar]
  12. Hahn C. S., Hahn Y. S., Braciale T. J., Rice C. M. Infectious Sindbis virus transient expression vectors for studying antigen processing and presentation. Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2679–2683. doi: 10.1073/pnas.89.7.2679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Haynes B. F., Pantaleo G., Fauci A. S. Toward an understanding of the correlates of protective immunity to HIV infection. Science. 1996 Jan 19;271(5247):324–328. doi: 10.1126/science.271.5247.324. [DOI] [PubMed] [Google Scholar]
  14. Honda M., Matsuo K., Nakasone T., Okamoto Y., Yoshizaki H., Kitamura K., Sugiura W., Watanabe K., Fukushima Y., Haga S. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10693–10697. doi: 10.1073/pnas.92.23.10693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hu S. L., Abrams K., Barber G. N., Moran P., Zarling J. M., Langlois A. J., Kuller L., Morton W. R., Benveniste R. E. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science. 1992 Jan 24;255(5043):456–459. doi: 10.1126/science.1531159. [DOI] [PubMed] [Google Scholar]
  16. Huang H. V., Rice C. M., Xiong C., Schlesinger S. RNA viruses as gene expression vectors. Virus Genes. 1989 Sep;3(1):85–91. doi: 10.1007/BF00301989. [DOI] [PubMed] [Google Scholar]
  17. Jahrling P. B., Stephenson E. H. Protective efficacies of live attenuated and formaldehyde-inactivated Venezuelan equine encephalitis virus vaccines against aerosol challenge in hamsters. J Clin Microbiol. 1984 Mar;19(3):429–431. doi: 10.1128/jcm.19.3.429-431.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Javaherian K., Langlois A. J., LaRosa G. J., Profy A. T., Bolognesi D. P., Herlihy W. C., Putney S. D., Matthews T. J. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science. 1990 Dec 14;250(4987):1590–1593. doi: 10.1126/science.1703322. [DOI] [PubMed] [Google Scholar]
  19. Kaplan A. H., Manchester M., Everitt L., Swanstrom R. Analysis of human immunodeficiency virus type 1 protease activity in eukaryotic and bacterial cells. Methods Enzymol. 1994;241:58–69. doi: 10.1016/0076-6879(94)41059-3. [DOI] [PubMed] [Google Scholar]
  20. Karacostas V., Nagashima K., Gonda M. A., Moss B. Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. Proc Natl Acad Sci U S A. 1989 Nov;86(22):8964–8967. doi: 10.1073/pnas.86.22.8964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kinney R. M., Esposito J. J., Mathews J. H., Johnson B. J., Roehrig J. T., Barrett A. D., Trent D. W. Recombinant vaccinia virus/Venezuelan equine encephalitis (VEE) virus protects mice from peripheral VEE virus challenge. J Virol. 1988 Dec;62(12):4697–4702. doi: 10.1128/jvi.62.12.4697-4702.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Koup R. A., Safrit J. T., Cao Y., Andrews C. A., McLeod G., Borkowsky W., Farthing C., Ho D. D. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994 Jul;68(7):4650–4655. doi: 10.1128/jvi.68.7.4650-4655.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kündig T. M., Bachmann M. F., DiPaolo C., Simard J. J., Battegay M., Lother H., Gessner A., Kühlcke K., Ohashi P. S., Hengartner H. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science. 1995 Jun 2;268(5215):1343–1347. doi: 10.1126/science.7761853. [DOI] [PubMed] [Google Scholar]
  24. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  25. Lehner T., Bergmeier L. A., Tao L., Panagiotidi C., Klavinskis L. S., Hussain L., Ward R. G., Meyers N., Adams S. E., Gearing A. J. Targeted lymph node immunization with simian immunodeficiency virus p27 antigen to elicit genital, rectal, and urinary immune responses in nonhuman primates. J Immunol. 1994 Aug 15;153(4):1858–1868. [PubMed] [Google Scholar]
  26. Lehner T., Wang Y., Cranage M., Bergmeier L. A., Mitchell E., Tao L., Hall G., Dennis M., Cook N., Brookes R. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med. 1996 Jul;2(7):767–775. doi: 10.1038/nm0796-767. [DOI] [PubMed] [Google Scholar]
  27. Liljeström P., Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (N Y) 1991 Dec;9(12):1356–1361. doi: 10.1038/nbt1291-1356. [DOI] [PubMed] [Google Scholar]
  28. Lovett A. E., Hahn C. S., Rice C. M., Frey T. K., Wolinsky J. S. Rubella virus-specific cytotoxic T-lymphocyte responses: identification of the capsid as a target of major histocompatibility complex class I-restricted lysis and definition of two epitopes. J Virol. 1993 Oct;67(10):5849–5858. doi: 10.1128/jvi.67.10.5849-5858.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Martin S. J., Vyakarnam A., Cheingsong-Popov R., Callow D., Jones K. L., Senior J. M., Adams S. E., Kingsman A. J., Matear P., Gotch F. M. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses. AIDS. 1993 Oct;7(10):1315–1323. [PubMed] [Google Scholar]
  30. Matsui M., Hioe C. E., Frelinger J. A. Roles of the six peptide-binding pockets of the HLA-A2 molecule in allorecognition by human cytotoxic T-cell clones. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):674–678. doi: 10.1073/pnas.90.2.674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Moore J. P., Cao Y., Leu J., Qin L., Korber B., Ho D. D. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol. 1996 Jan;70(1):427–444. doi: 10.1128/jvi.70.1.427-444.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Mossman S. P., Bex F., Berglund P., Arthos J., O'Neil S. P., Riley D., Maul D. H., Bruck C., Momin P., Burny A. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J Virol. 1996 Mar;70(3):1953–1960. doi: 10.1128/jvi.70.3.1953-1960.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Muster T., Ferko B., Klima A., Purtscher M., Trkola A., Schulz P., Grassauer A., Engelhardt O. G., García-Sástre A., Palese P. Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus. J Virol. 1995 Nov;69(11):6678–6686. doi: 10.1128/jvi.69.11.6678-6686.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Newton S. M., Joys T. M., Anderson S. A., Kennedy R. C., Hovi M. E., Stocker B. A. Expression and immunogenicity of an 18-residue epitope of HIV1 gp41 inserted in the flagellar protein of a Salmonella live vaccine. Res Microbiol. 1995 Mar-Apr;146(3):203–216. doi: 10.1016/0923-2508(96)80276-2. [DOI] [PubMed] [Google Scholar]
  35. Paul W. E. Can the immune response control HIV infection? Cell. 1995 Jul 28;82(2):177–182. doi: 10.1016/0092-8674(95)90304-6. [DOI] [PubMed] [Google Scholar]
  36. Porter D. C., Melsen L. R., Compans R. W., Morrow C. D. Release of virus-like particles from cells infected with poliovirus replicons which express human immunodeficiency virus type 1 Gag. J Virol. 1996 Apr;70(4):2643–2649. doi: 10.1128/jvi.70.4.2643-2649.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Ratner L., Fisher A., Jagodzinski L. L., Mitsuya H., Liou R. S., Gallo R. C., Wong-Staal F. Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res Hum Retroviruses. 1987 Spring;3(1):57–69. doi: 10.1089/aid.1987.3.57. [DOI] [PubMed] [Google Scholar]
  38. Salk J., Bretscher P. A., Salk P. L., Clerici M., Shearer G. M. A strategy for prophylactic vaccination against HIV. Science. 1993 May 28;260(5112):1270–1272. doi: 10.1126/science.8098553. [DOI] [PubMed] [Google Scholar]
  39. Shafferman A., Jahrling P. B., Benveniste R. E., Lewis M. G., Phipps T. J., Eden-McCutchan F., Sadoff J., Eddy G. A., Burke D. S. Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences. Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7126–7130. doi: 10.1073/pnas.88.16.7126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Staats H. F., Jackson R. J., Marinaro M., Takahashi I., Kiyono H., McGhee J. R. Mucosal immunity to infection with implications for vaccine development. Curr Opin Immunol. 1994 Aug;6(4):572–583. doi: 10.1016/0952-7915(94)90144-9. [DOI] [PubMed] [Google Scholar]
  41. Strauss J. H., Strauss E. G. The alphaviruses: gene expression, replication, and evolution. Microbiol Rev. 1994 Sep;58(3):491–562. doi: 10.1128/mr.58.3.491-562.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Xiong C., Levis R., Shen P., Schlesinger S., Rice C. M., Huang H. V. Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science. 1989 Mar 3;243(4895):1188–1191. doi: 10.1126/science.2922607. [DOI] [PubMed] [Google Scholar]
  43. Zhou X., Berglund P., Rhodes G., Parker S. E., Jondal M., Liljeström P. Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine. 1994 Dec;12(16):1510–1514. doi: 10.1016/0264-410x(94)90074-4. [DOI] [PubMed] [Google Scholar]
  44. Zhou X., Berglund P., Zhao H., Liljeström P., Jondal M. Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):3009–3013. doi: 10.1073/pnas.92.7.3009. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES